The Value of In Vitro Diagnostic Testing in Medical Practice: A Status Report

In vitro diagnostic (IVD) investigations are indispensable for routine patient management. Appropriate testing allows early-stage interventions, reducing late-stage healthcare expenditure (HCE). To investigate HCE on IVDs in two developed markets and to assess the perceived value of IVDs on clinical...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2016-03, Vol.11 (3), p.e0149856-e0149856
Main Authors: Rohr, Ulrich-Peter, Binder, Carmen, Dieterle, Thomas, Giusti, Francesco, Messina, Carlo Guiseppe Mario, Toerien, Eduard, Moch, Holger, Schäfer, Hans Hendrik
Format: Article
Language:English
Subjects:
Algorithms
Apoptosis
Biology and Life Sciences
Breast cancer
Cancer therapies
Cardiology - economics
Clinical decision making
Cost analysis
Cost-Benefit Analysis
Data Collection
Decision making
Decision Support Systems, Clinical
Diagnostic reagents
Diagnostic systems
Diagnostic tests
Diagnostic Tests, Routine - economics
Diagnostic Tests, Routine - statistics & numerical data
Germany
Health care
Health Care Costs
Hospitals
Humans
Internal medicine
Laboratories
Markers
Medical diagnosis
Medical Oncology - economics
Medical personnel
Medical screening
Medical tests
Medicine
Medicine and Health Sciences
Methods
Patients
People and Places
Physicians
Practice Patterns, Physicians
Surveys and Questionnaires
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In vitro diagnostic (IVD) investigations are indispensable for routine patient management. Appropriate testing allows early-stage interventions, reducing late-stage healthcare expenditure (HCE). To investigate HCE on IVDs in two developed markets and to assess the perceived value of IVDs on clinical decision-making. Physician-perceived HCE on IVD was evaluated, as well as desired features of new diagnostic markers. Past and current HCE on IVD was calculated for the US and Germany. A total of 79 US/German oncologists and cardiologists were interviewed to assess the number of cases where: physicians ask for IVDs; IVDs are used for initial diagnosis, treatment monitoring, or post-treatment; and decision-making is based on an IVD test result. A sample of 201 US and German oncologists and cardiologists was questioned regarding the proportion of HCE they believed to be attributable to IVD testing. After disclosing the actual IVD HCE, the physician's perception of the appropriateness of the amount was captured. Finally, the association between physician-rated impact of IVD on decision-making and perceived contribution of IVD expenditure on overall HCE was assessed. IVD costs account for 2.3% and 1.4% of total HCE in the US and Germany. Most physicians (81%) believed that the actual HCE on IVDs was >5%; 19% rated the spending correctly (0-4%, p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0149856